Navigation Links
Telik Announces Third Quarter 2011 Financial Results
Date:11/3/2011

PALO ALTO, Calif., Nov. 3, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $2.8 million, or $0.05 per share, for the third quarter ended September 30, 2011, compared with a net loss of $4.7 million, or $0.09 per share, for the comparable period in 2010.

For the quarter ended September 30, 2011, total operating costs and expenses were $2.9 million, compared with $4.7 million in the third quarter of 2010.  Operating expenses in the 2011 third quarter included stock-based compensation expense of approximately $0.5 million.  Operating expenses were approximately 39% lower in the third quarter of 2011 compared with the same period in 2010, primarily due to lower headcount, clinical development and facility expenses.

For the nine months ended September 30, 2011, Telik reported a net loss of $9.5 million, or $0.18 per share, compared with a net loss of $14.9 million, or $0.28 per share, for the same period in 2010.  Total operating expenses for the first nine months of 2011 were $9.6 million, compared with $15.1 million for the same period in 2010.  Operating expenses in the first nine months of 2011 included approximately $1.2 million in stock-based compensation expense.  The reduction in operating expenses of approximately 37% in the first nine months of 2011 compared with the same period in 2010 was primarily due to lower headcount, reduced clinical trial expenses, lower stock-based compensation and lower facility costs.

At September 30, 2011, Telik had $14.0 million in cash, cash equivalents and investments including restricted investments, compared to $24.1 million at December 31, 2010.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2011201020112010Operating costs and expenses:Research and development

$
,305$
2,569$  4,464$
8,202General and administrative

1,5502,1015,0906,856Total operating costs and expenses

2,8554,6709,55415,058Loss from operations

(2,855)(4,670)(9,554)(15,058)Interest and other income (expense), net

71731132Net loss

$
(2,848)$
(4,653)$ (9,523)$ (14,926)Basic and diluted net loss per share

$
(0.05)$
(0.09)$   (0.18)$
(0.28)Weighted average shares used to calculate basic and diluted net loss per share

53,96253,55353,87053,514Selected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,20112010Cash, cash equivalents, investments and restricted investments

$
4,033$
24,064Total assets

14,93625,029Stockholders' equity

10,27318,369
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
2. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
4. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
5. Telik Announces First Quarter 2011 Financial Results
6. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
7. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
8. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
9. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
10. Telik Announces Presentation at American Society of Hematology Annual Meeting
11. Telik Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/12/2017)...  Eli Lilly and Company (NYSE: LLY ) ... resolve pending patent litigation in the U.S. District Court for ... the Cialis ® (tadalafil) unit dose patent. This patent ... part of the agreement, Cialis exclusivity is now expected to ... "The unit dose patent for Cialis is valid and infringed ...
(Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Wettstein Agencies, ... communities in the greater Denver region, is announcing a charity drive to help ... rare kind of epilepsy. , Until a few months ago, Dominik was a ...
(Date:7/21/2017)... Helena, AL (PRWEB) , ... July 21, 2017 ... ... that offers insurance assistance and financial planning services to communities in the greater ... that promises to provide resources to underprivileged young people in the region. , ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... Theater of Witness , was awarded a $300,000 grant from The Pew ... fosters empathy, comfort with ambiguity and the recognition of one’s own limits among ...
(Date:7/21/2017)... ... ... The Margarian Law Firm has filed a class action lawsuit ... containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ale products. ... Dry Ginger Ale claims on its bottle that it is made from real ginger. ...
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has launched a ... acceptance to a residency in a United States hospital. Being accepted into a ... , According to data released by the ECFMG®, every year, 50 percent of ...
Breaking Medicine News(10 mins):